And, although the amount of weight lost was statistically significant, the average loss was 2.4 pounds (1.1 kg), not necessarily clinically significant
any such effect should be considered in the context of individual experience rather than as a certainty
Patients prescribed GLP-1s should be monitored for far longer, particularly for slow-growing diseases like breast and thyroid cancers, Dr
1-8 Recent European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes state that GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide extended release [ER], dulaglutide, efpeglenatide) should be considered for glucose-lowering treatment in patients with T2D at risk of or with heart failure (HF
They also acknowledge the support of technician Tarek Abdel Hamid for his role in managing animal housing
Patients must maintain documentation showing the prescription was issued for a diagnosed conditiontypically type 2 diabetes, prediabetes, or documented obesity with comorbidities like hypertension or sleep apnea
